Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 12, 2016
Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical TrialsW Joseph Herring, Kathleen M Connor, Ellen Snyder, et al.The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 22, 2017
Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical TrialsW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.Journal of Clinical Pharmacology|October 15, 2013
Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patientsHong Sun, Catherine MacLeod, Kate Mostoller, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJonathan A Sugam, Seth Robey, Sokreine Suon, et al.Biological Psychiatry|December 21, 2014
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical TrialsW Joseph Herring, Kathryn M Connor, Neely Ivgy-May, et al.Scientific Reports|June 4, 2016
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to ManAnthony L Gotter, Mark S Forman, Charles M Harrell, et al.Pageof 4